Investment ProfessionalsBB Biotech AG
ISIN-No.: CH0038389992
YTD: -9.03%
Active share: 77.00
Anzahl Positionen: 23
New innovative drugs and technologies are powering sustainable momentum in the biotech sector
Focus on profitable companies and small and mid-cap companies with strong pipelines
Attractive dividend policy; Dividend payment of 5% p.a.
Indexed performance (as at: 13.06.2025)
Share price: EUR 32.25 (12.06.2025)
NAV: EUR 37.20 (12.06.2025)
Rolling performance (13.06.2025)
| Share Price | NAV | Benchmark | |
| 12.06.2024 - 12.06.2025 | -17.90% | -12.03% | -10.71% |
| 12.06.2023 - 12.06.2024 | -2.42% | 5.29% | 8.70% |
| 10.06.2022 - 12.06.2023 | -12.80% | 14.72% | 17.51% |
| 10.06.2021 - 10.06.2022 | -27.31% | -32.33% | -20.19% |
Annualized performance (13.06.2025)
| Share Price | NAV | Benchmark | |
| 1 year | -17.90% | -12.03% | -10.71% |
| 3 years | -11.27% | 2.05% | 4.58% |
| 5 years | -7.16% | -2.56% | 1.93% |
| 10 years | -0.20% | -0.26% | 1.46% |
| Since Inception p.a. | 10.13% | 10.68% | 10.06% |
Cumulative performance (13.06.2025)
| Share Price | NAV | Benchmark | |
| 1M | 3.37% | 1.78% | 7.38% |
| YTD | -9.03% | -12.22% | -10.30% |
| 1 year | -17.90% | -12.03% | -10.71% |
| 3 years | -30.15% | 6.26% | 14.36% |
| 5 years | -31.04% | -12.18% | 10.02% |
| 10 years | -1.97% | -2.54% | 15.63% |
| Since Inception | 1'325.87% | 1'534.86% | 1'298.66% |
Annual performance
| Share Price | NAV | Benchmark | |
| 2024 | -14.08% | 1.71% | 6.30% |
| 2023 | -15.21% | -1.29% | 1.26% |
| 2022 | -19.00% | -6.72% | -4.46% |
| 2021 | 13.34% | -7.79% | 7.39% |
Facts & Key figures
Investment Focus
BB Biotech actively invests worldwide in fast growing companies developing and marketing innovative biotech drugs. At least 90% of its shareholdings must be in listed companies, while always holding more than 50% of its assets in equity investments. Show moreShow less
Investment suitability & Risk
Low risk
High risk
General Information
| Investment Manager | Bellevue Asset Management AG |
| Custodian | Bank Julius Bär AG |
| Fund Administrator | Bellevue Asset Management AG |
| Auditor | Deloitte AG |
| Launch date | 09.11.1993 |
| Year end closing | 31. Dec |
| Management Fee | 1.10% |
| ISIN number | CH0038389992 |
| Valor number | 3838999 |
| Bloomberg | BBZA GY Equity |
| WKN | A0NFN3 |
Legal Information
| Legal form | Incorporate company |
| SFDR category | Article 8 |
Key data (31.05.2025, base currency CHF)
| Beta | 1.23 |
| Volatility | 29.96 |
| Tracking error | 13.68 |
| Active share | 77.00 |
| Correlation | 0.91 |
| Sharpe ratio | 0.06 |
| Information ratio | 0.17 |
| Jensen's alpha | 2.37 |
| No. of positions | 23 |
Portfolio as at 31.03.2025
Positions
Market capitalization
Breakdown by sector
Currency
Benefits & Risks
Benefits
- Unique opportunity for European investors to access the global biotech sector, a non-cyclical growth industry that is strongly supported by increasing demand, driven by demographic trends and life style changes.
- New innovative drugs and technologies are powering sustainable momentum in the biotech sector.
- Focus on a diversified portfolio of profitable companies as well as small and midcap companies with strong pipelines.
- Management Team with strong scientific and medical expertise. Renowned Board of Directors.
- Attractive dividend policy; Dividend payment of 5% p.a.
Risks
- BB Biotech actively invests in equities. Equities are subject to strong price fluctuations and so are also exposed to the risk of price losses.
- Biotech equities can be subject to sudden substantial price movements owning to market, sector or company factors.
- BB Biotech invests in foreign currencies, which means a corresponding degree of currency risk against the reference currency.
- The price investors pay or receive, like other listed shares, is determined by supply and demand and may be at a discount or premium to the underlying net asset value of the Company.
- BB Biotech may take a leverage of up to 15%, which may lead to even higher price movements compared to the underlying market.
Review / Outlook
We are still seeing fundamental progress in most of our portfolio companies. Our strategy focuses on companies pursuing transformative approaches in areas with high unmet medical needs. We are operating with increased caution. The US regulatory landscape has become more unpredictable. In this context, we are intensifying engagement with our portfolio companies to ensure preparedness across financing, manufacturing and supply chains, clinical development plans, regulatory pathways, and commercial execution.
We continue to prioritize long-term value creation by investing in deeply differentiated products and companies with clear clinical and commercial pathways. We are backing companies with sharpened investment hypotheses, improved risk-adjusted entry points, and greater capital discipline. Structural changes may take time to settle, but we view this period as one of strategic positioning.
Please find below selected highlights from a few of BB Biotech´s portfolio companies:
Incyte (+3.8%, in USD) announced on May 15 that the FDA has approved Zynyz® (retifanlimab-dlwr) in combination with carboplatin and paclitaxel (chemotherapy) for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). In addition, the FDA granted approval for Zynyz as a single agent for the treatment of adult patients with locally recurrent or with metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy.
Revolution Medicines (-2.4%, in USD) announced on May 14 that the first patient has been dosed in RASolve 301, a global, randomized, open-label Phase III clinical trial. RASolve 301 will evaluate the safety and efficacy of daraxonrasib (RMC-6236) in patients with previously treated, locally advanced or metastatic RAS mutant non-small cell lung cancer (NSCLC) compared to docetaxel chemotherapy.
Argenx (-11.1%, in USD) announced on May 8 first quarter results and a business update. Argenx generated global product net sales (inclusive of both VYVGART and VYVGART SC) of USD 790 mn in the first quarter of 2025. Multiple regulatory decisions on approval for PFS are completed or underway: Positive recommendation from Committee for Medicinal Products for Human Use (CHMP) of European Medicines Agency (EMA) for VYVGART-SC (PFS and vial) for CIDP.
Documents
Show moreShow less
